A Phase 2b Randomised Trial of the Candidate Malaria Vaccines FP9 ME-TRAP and MVA ME-TRAP among Children in Kenya

Bejon, Philip; Mwacharo, Jedidah; Kai, Oscar; Mwangi, Tabitha; Milligan, Paul; Todryk, Stephen; Keating, Sheila; Lang, Trudie; Lowe, Brett; Gikonyo, Caroline; Molyneux, Catherine; Fegan, Greg; Gilbert, Sarah C.; Peshu, Norbert; Marsh, Kevin; Hill, Adrian V. S.
October 2006
PLoS Clinical Trials;Oct2006, Vol. 3 Issue 10, p0001
Academic Journal
Objective: The objective was to measure the efficacy of the vaccination regimen FFM ME-TRAP in preventing episodes of clinical malaria among children in a malaria endemic area. FFM ME-TRAP is sequential immunisation with two attenuated poxvirus vectors (FP9 and modified vaccinia virus Ankara), which both deliver the pre-erythrocytic malaria antigen construct multiple epitope--thrombospondin-related adhesion protein (ME-TRAP). Design: The trial was randomised and double-blinded. Setting: The setting was a rural, malaria-endemic area of coastal Kenya. Participants: We vaccinated 405 healthy 1- to 6-year-old children. Interventions: Participants were randomised to vaccination with either FFM ME-TRAP or control (rabies vaccine). Outcome Measures: Following antimalarial drug treatment children were seen weekly and whenever they were unwell during nine months of monitoring. The axillary temperature was measured, and blood films taken when febrile. The primary analysis was time to a parasitaemia of over 2,500 parasites/µl. Results: The regime was moderately immunogenic, but the magnitude of T cell responses was lower than in previous studies. In intention to treat (ITT) analysis, time to first episode was shorter in the FFM ME-TRAP group. The cumulative incidence of febrile malaria was 52/190 (27%) for FFM ME-TRAP and 40/197 (20%) among controls (hazard ratio = 1.52). This was not statistically significant (95% confidence interval [CI] 1.0-2.3; p = 0.14 by log-rank). A group of 346 children were vaccinated according to protocol (ATP). Among these children, the hazard ratio was 1.3 (95% CI 0.8-2.1; p = 0.55 by log-rank). When multiple malaria episodes were included in the analyses, the incidence rate ratios were 1.6 (95% CI 1.1-2.3); p = 0.017 for ITT, and 1.4 (95% CI 0.9-2.1); p = 0.16 for ATP. Haemoglobin and parasitaemia in cross-sectional surveys at 3 and 9 mo did not differ by treatment group. Among children vaccinated with FFM ME-TRAP, there was no correlation between immunogenicity and malaria incidence. Conclusions: No protection was induced against febrile malaria by this vaccine regimen. Future field studies will require vaccinations with stronger immunogenicity in children living in malarious areas.


Related Articles

  • Malaria vaccine on the horizon. Dawood, Richard // Conde Nast Traveler;Jan2000, Vol. 35 Issue 1, p30 

    Reports on the scientific breakthroughs in developing a vaccine against malaria made by scientists in Atlanta, Georgia. Ability of the malaria parasite to build resistance against medications; Toughest challenge in research works about malaria; Advantages of the antimalarial drug, Malarone over...

  • Designing antimalarials. Gillis, Anna Maria // BioScience;Sep94, Vol. 44 Issue 8, p523 

    Reports on the designing of new antimalarial compounds in curing malaria. Details of preliminary study; Background on anopheles mosquito, malaria; Description of Gary H. Posner, Chang Ho Oh's research; Definition of semisynthetics; Benefits of smaller semisynthetic trioxanes; Effects of...

  • Malaria prophylaxis.  // Pulse;6/3/2002, Vol. 62 Issue 22, p92 

    Provides information on malaria prophylaxis. Ways to avoid malaria; List of travel destinations where immunization for malaria prophylaxis is recommended; Recommended regimens; Alternative regimens; Doses of antimalarial prophylactics that are required for children.

  • Safety and Reactogenicity of an MSP-1 Malaria Vaccine Candidate: A Randomized Phase Ib Dose-Escalation Trial in Kenyan Children. Withers, Mark R.; McKinney, Denise; Ogutu, Bernhards R.; Waitumbi, John N.; Milman, Jessica B.; Apollo, Odika J.; Allen, Otieno G.; Tucker, Kathryn; Soisson, Lorraine A.; Diggs, Carter; Leach, Amanda; Wittes, Janet; Dubovsky, Filip; Stewart, V. Ann; Remich, Shon A.; Cohen, Joe; Ballou, W. Ripley; Holland, Carolyn A.; Lyon, Jeffrey A.; Angov, Evelina // PLoS Clinical Trials;Nov2006, Vol. 3 Issue 11, p0001 

    Objective: Our aim was to evaluate the safety, reactogenicity, and immunogenicity of an investigational malaria vaccine. Design: This was an age-stratified phase Ib, double-blind, randomized, controlled, dose-escalation trial. Children were recruited into one of three cohorts (dosage groups) and...

  • Distribution of Insecticide-Treated Bednets During an Integrated Nationwide Immunization Campaign -- Togo, West Africa, December 2004.  // MMWR: Morbidity & Mortality Weekly Report;10/7/2005, Vol. 54 Issue 39, p994 

    Reports on the distribution of bednets during a nationwide immunization campaign against malaria in children in Togo, West Africa in December 2004. Prevalence of malaria among children; Information on the MOH Expanded Program for Immunization campaign; Percentage of children who receive the...

  • Antibodies to malaria vaccine candidates are associated with chloroquine or sulphadoxine/pyrimethamine treatment efficacy in children in an endemic area of Burkina Faso.  // Malaria Journal;2012, Vol. 11 Issue 1, p79 

    The article presents the findings of a research on the relationship between antibodies and anti-malarial drug treatment outcomes in Burkina Faso. It discusses the methodology of the research. It concludes that acquired anti-malarial antibodies may play an important role in the efficacy of...

  • Quarter-century quest for malaria vaccine shows signs of success. Opar, Alisa // Nature Reviews Drug Discovery;Dec2011, Vol. 10 Issue 12, p887 

    The article reports that GlaxoSmithKline (GSK) led ongoing trial of the vaccine candidate RTS,S, provides children with nearly 50% protection from severe bouts of the disease. The large-scale trial enrolled over 15,000 children aged either 6-12 weeks or 5-17 months in seven countries in...

  • Extended Follow-Up Following a Phase 2b Randomized Trial of the Candidate Malaria Vaccines FP9 ME-TRAP and MVA ME-TRAP among Children in Kenya. Bejon, Philip; Ogada, Edna; Mwangi, Tabitha; Milligan, Paul; Lang, Trudie; Fegan, Greg; Gilbert, Sarah C.; Peshu, Norbert; Marsh, Kevin; Hill, Adrian V. S. // PLoS Clinical Trials;Aug2007, Vol. 4 Issue 8, p1 

    Background. "FFM ME-TRAP" is sequential immunisation with two attenuated poxvirus vectors (FP9 and modified vaccinia virus Ankara) delivering the pre-erythrocytic malaria antigen ME-TRAP. Over nine months follow-up in our original study, there was no evidence that FFM ME-TRAP provided protection...

  • Incorporating a quiz into informed consent processes: Qualitative study of participants' reactions. Molyneux, Sassy; Gikonyo, Caroline; Marsh, Vicki; Bejon, Philip // Malaria Journal;2007, Vol. 6, p145 

    Background: Formal checks of participant understanding are now widely recommended to improve informed consent processes. However, the views of the participants these assessments are designed to protect are rarely considered. In this paper the findings of a qualitative study aimed at documenting...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics